Potentially prothrombotic abnormalities of coagulation in benign intracranial hypertension

Journal of Neurology Neurosurgery and Psychiatry

Volumn 62, Issue 3, 1997, Pages 229-233

  Sussman, J ^a   Leach, M ^b   Greaves, M ^c   Malia, R ^b   Davies Jones, G A B ^a  

^a Department of Neurology ^*  (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Antiphospholipid antibodies; Benign intracranial hypertension; Pseudotumour cerebri

Indexed keywords

ANTITHROMBIN III; CARDIOLIPIN ANTIBODY; FIBRINOGEN; KAOLIN; LUPUS ANTICOAGULANT; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S;

ADULT; ANTITHROMBIN III DEFICIENCY; ARTICLE; BLOOD CLOTTING TIME; BRAIN PSEUDOTUMOR; CEREBROSPINAL FLUID DRAINAGE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MALE; POLYCYTHEMIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RETROSPECTIVE STUDY; THROMBOCYTOSIS; VEIN THROMBOSIS;

EID: 0030991417     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.62.3.229     Document Type: Article

References (36)

1. Hoffman HJ. How is pseudotumor cerebri diagnosed? Arch Neurol 1982;43:167-8.
2. Corbett JJ, Mehta MP. Cerebrospinal fluid pressure in normal obese subjects and patients with pseudotumor cerebri. Neurology 1983;33:1386-8.
3. Dandy WE. Intracranial pressure without brain tumor. Ann Surg 1937;106:492-513.
4. Wall M. Idiopathic intracranial hypertension. Neurol Clin 1991;9:73-95.
5. Corbett JJ, Savino PJ, Thompson S, et al. Visual loss in pseudotumor cerebri. Arch Neurol 1982;33:1386-8.
6. Boddie HG, Banna M, Bradley WG. Benign intracranial hypertension. Brain 1974;97:313-26.
7. Foley J. Benign forms of intracranial hypertension - "toxic" and "ototic" forms. Brain 1955;78:1-41.
8. Janny P, Chazal J, Colnet G, Irthum B, Georget A-M. Benign intracranial hypertension and disorders of CSF absorption. Surg Neurol 1980;15:168-74.
9. Melamed E, Rchmilewitz EA, Reches A, Lavy S. Aseptic cavernous sinus thrombosis after internal carotid arterial occlusion in polycythaenia vera. J Neurol Neurosurg Psychiatry 1976;39:320-4.
10. Esack A, Thompson G, Burmester H. Benign intracranial hypertension and essential thrombocythaemia. J Neurol Neurosurg Psychiatry 1989;52:914.
11. Wasan H, Mansi JL, Benjamin S, Powles R, Cunningham D. Myeloma and benign intracranial hypertension. BMJ 1992;304:685.
12. Massons J, Arboix A, Oliveres M, Besses C, Munoz C, Titus F. Cerebral venous thrombosis and hereditary protein C deficiency. Neurologia 1992;7:34-8.
13. Johnston I. Reduced CSF absorption syndrome. Reappraisal of benign intracranial hypertension and related conditions. Lancet 1973;ii:418-21.
14. Greaves M, Davies-Jones GAB. Neurological abnormalities associated with coagulopathies. Elsevier, 1993.
15. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematologica 1957;17: 237-46.
16. Creagh MD, Maglia RG, Cooper SM, Smith AR, Duncan SLB, Greaves M. Screening for the lupus anticoagulant and anticardiolipin antibody in women with fetal loss. J Clin Pathol 1991;44:45-7.
17. Greaves M, Preston FE. Clinical and laboratory aspects of thrombophilia, in Recent advances in Blood Coagulation 1993. London: Churchill Livingstone, 119-40.
18. Machin SJ, Giddings J, Greaves M, Hutton R. Detection of the lupus-like anticoagulant: current laboratory practice in the United Kingdom. J Clin Pathol 1990;43:73-9.
19. Harris EN, Gharavie AE, Hegde U, et al. Anticardiolpin antibodies in autoimmune thrombocytopaenic purpura. Br J Haematol 1985;59:231-4.
20. Levine SR, Welch KMA. Spectrum of neurological diseases associated with antiphospholipid antibody. Arch Neurol 1987;44:876-83.
21. Koster T, Rosendaal FR, Reitsma PH, et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis - a case control study of plasma levels and DNA polymorphism. Thrombos Hamostas 1994;71:719-22.
22. Ogston D, McAndrew GM. Fibrinolysis in obesity. Lancet 1974;2:1205-7.
23. Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. BMJ 1979;1: 153-6.
24. Balleisen L, Bailey J, Epping PH, Schulte H, Van de Loo J. Epidemiological study on factor VIII and fibrinogen in an industrial population. I: borderline data on the relation to age, body-weight, smoking, alcohol, pill-using and menopause. Thrombos Haemostas 1985;54:475-9.
25. Vyas CK, Talwar KK, Bhatnagar V, et al. Steroid-induced benign intracranial hypertension. Postgrad Med J 1981; 57:181-2.
26. Greer M. Benign intracranial hypertension: II following corticosteroid therapy. Neurology 1963;13:439-41.
27. Neville BGR, Wilson J. Benign intracranial hypertension following corticosteroid withdrawal in children. BMJ 1970;3:554-6.
28. Digre KB, Corbett JJ. Pseudotumor cerebri in men. Arch Neurol 1988;45:866-72.
29. Griffin JP. A review of the literature on benign intracranial hypertension associated with medication. Adverse Drug React Toxicol Rev 1992;11:41-58.
30. Risdale L, Moseley I. Thoracolumbar intraspinal tumours. Presenting features of raised intracranial pressure. J Neurol Neurosurg Psychiatry 1978;41:737-45.
31. Pierro L, Brancato R, Zaganelli E, Guarisco L, Lazetta P. Ocular involvement in acute lymphoblastic leukaemia: an echographic study. Int Ophthalmol 1992;16:159-62.
32. Prockop LD, Fishman RA. Experimental pneumococcal meningitis: permiability changes influencing the concentration of sugars and macromolecules in cerebrospinal fluid. Arch Neurol 1968;19:449-63.
33. Karsarkis EJ, Maffea CJ, Johnson RN, Butler AB, Bass NH. Intracranial hypertension in vitamin A deficient rats: reversible metabolic derangement of cerebrospinal fluid absorption. Neurology 1978;28:349.
34. Hayes KC. The fine structure of vitamin A deficiency II: arachnoid granulations and CSF pressure. Brain 1971; 94:213-24.
35. Hill MB, Phipps JL, Malia RG, et al. Characterisation and specificity of anti-endothelial cell membrane antibodies and their relationship to thrombosis in primary antiphospholipid syndrome (APS). Clin Exp Immunol 1995; 102:368-72.
36. Svensson PGA, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.